Stockscreener 앱 받기
0.5891
1.05%
0.00612
시간 외 거래:
.59
0.00088
+0.15%
전일 마감가:
$0.583
열려 있는:
$0.607
하루 거래량:
86,492
Relative Volume:
0.13
시가총액:
$7.22M
수익:
$1.85M
순이익/손실:
$-5.56M
주가수익비율:
-0.7769
EPS:
-0.7583
순현금흐름:
-
1주 성능:
-4.21%
1개월 성능:
-32.24%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.56
$0.63
1주일 범위
$0.55
$0.649
52주 변동 폭
$0.5111
$14.09
20 20 Biolabs Inc Stock (AIDX) Company Profile
명칭
20 20 Biolabs Inc
전화
(240) 453-6339
주소
9430 KEY WEST AVENUE, ROCKVILLE
Compare AIDX vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AIDX
20 20 Biolabs Inc
|
0.5891 | 7.22M | 1.85M | -5.56M | 0 | -0.7583 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
20 20 Biolabs Inc 주식(AIDX)의 최신 뉴스
What Factors Led to 20/20 Biolabs' Dramatic Stock Collapse - Kavout | AI
20/20 BioLabs reports Q2 MCED revenue to be highest to date - Investing.com
20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth - Yahoo Finance
Virax Biolabs | 20-F: Registration statement / Annual report / Transition report - Moomoo
AIDX SEC Filings20/20 Biolabs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
[20-F] Virax Biolabs Group Ltd Files Annual Report (Foreign Issuer) | VRAX SEC FilingForm 20-F - Stock Titan
20/20 Biolabs to present OneTest webinar outlining Medicare pathway, modeling and reimbursement plan - TradingView
OneTest growth vision: 20/20 Biolabs (AIDX) targets Medicare MCED market - Stock Titan
20/20 BioLabs’ Multi-Cancer Early Detection Test Now Available to Evexia Diagnostics' 40,000+ U.S. Practitioners - The National Law Review
20/20 Biolabs Inc. (AIDX) Edges Higher in Low-Price Territory as Support HoldsHull Moving Average - dars.gov.et
20/20 Biolabs, Inc. Actuals & Estimates (NASDAQ:AIDX) - TradingView
Price to sales forward of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
Price to book forward of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
Price to earnings forward of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
AIDX | 20/20 Biolabs, Inc. Common Executive Compensation - Quiver Quantitative
Large share authorization and new equity plan up for 20/20 Biolabs (AIDX) vote - Stock Titan
20/20 BioLabs Bets on Radical Transparency with Monthly Investor Calls - BriefGlance
20/20 BioLabs Launches Monthly Investor Webinar Series to Enhance Shareholder Communication - Quiver Quantitative
20/20 BioLabs starts monthly webinars, with a OneTest discount for attendees - Stock Titan
20/20 Biolabs, Inc.(NasdaqCM: AIDX) added to S&P TMI Index - marketscreener.com
AIDX Price Today: 20/20 Biolabs, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Meet Greater Washington's newest publicly traded companiesWashington Business Journal - The Business Journals
AIDX - Finviz
20/20 Biolabs Inc. (AIDX) Surges 13.6%: Breaking Out on Heavy VolumeSign of Strength - dars.gov.et
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Gapping stocks in Monday's session - ChartMill
10 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Why Tower Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Trending Stocks Today | Aspire Biopharma up 6.03% Post-Market - Moomoo
Get insights into the top gainers and losers of Friday's after-hours session. - ChartMill
20/20 Biolabs (AIDX) Surges 10.86%: Key Levels and Market SentimentETF AUM Growth - newsline.com
20/20 Biolabs (AIDX) Dips 7.75% – Key Support Test in FocusFactor Crowding - newsline.com
20/20 Biolabs (AIDX) Slumps 7.75% as Stock Nears Key $0.76 Support LevelFactor Rotation - newsline.com
Director Kathryn Gregory exits Longevity Health Holdings (XAGE) board without dispute - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
20/20 Biolabs (NASDAQ: AIDX) asks shareholders to raise authorized shares to 500M - Stock Titan
20/20 Biolabs, Inc. Files Form 8-K Announcing Amended and Restated Bylaws and Nasdaq Listing as Emerging Growth Company - Minichart
20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters - The Manila Times
20/20 Biolabs' OneTest™ Selected for Vermont Firefighter Cancer Screening Initiative, Expected to Generate $500,000 in Revenue - Quiver Quantitative
20/20 Biolabs, Inc.Common Stock (Nasdaq:AIDX) Stock Quote - The Chronicle-Journal
20/20 Biolabs (NASDAQ: AIDX) cuts quorum for shareholder meetings - Stock Titan
No Analysis Provided - StocksToTrade
AIDX Slides As 20/20 Biolabs Inc. Faces Heavy Selling - timothysykes.com
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand - Sahm
Maxim Group Maintains 20/20 BIOLABS INC(AIDX.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
20/20 Biolabs: Buy Rating Reiterated on Growth Outlook and OneTest Momentum; $5 Price Target Maintained - TipRanks
AIDX Stock Slides As 20/20 Biolabs Tests Key Support - timothysykes.com
20/20 Biolabs stock surges on Ebola testing plans By Investing.com - Investing.com Australia
20/20 Biolabs stock surges on Ebola testing plans - Investing.com India
20 20 Biolabs Inc (AIDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.36%
자본화:
|
볼륨(24시간):